Drug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment

Similar documents
Joseph S. Weiner, MD, PC Patient History Form

ACTG Adherence Follow Up Questionnaire

PATIENT SURVEY FOR ADMINISTRATIVE USE ONLY. TO BE COMPLETED BY STUDY COORDINATOR.

GoPrivateMD General Information & History

Adapted and translated by Elizabeth Barrera-Cancedda from the Tuberculosis Resistente rotafolio produced by PARTNERS TB CONTROL Grupo IECA, Peru.

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Patient General Information

MEDICAL QUESTIONNAIRE (female)

The New Mexico Refugee Symptom Checklist-121 (NMRSCL-121)

Emotional Relationships Social Life Sexually Recreation

Medical condition SELF Mother Father Sibling (list brother or sister) Anxiety Bipolar disorder Heart Disease Depression Diabetes High Cholesterol

MEDICAL DATA SHEET For Patients 18 years of age and older

Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor

JUST FOR KIDS SELECTED IMPORTANT SAFETY INFORMATION

New Patient Medical History Intake Form

What do you believe is causing your most important health concern?

RHEUMATOLOGY PATIENT HISTORY FORM

MEDICAL QUESTIONNAIRE (male)

For the Patient: Paclitaxel Other names: TAXOL

MEDICATION GUIDE Mefloquine Hydrochloride Tablets, USP

What is the most important information I should know about bortezomib? What should I discuss with my healthcare provider before receiving bortezomib?

PATIENT INFORMATION LEAFLET AMLOC RANGE

Where There Is No Doctor 2017

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions

DePaul Pediatric Health Questionnaire (Child Version)

Patient Intake Form for Acupuncture Treatment at Infinite Healing

Methotrexate. About This Drug. Possible Side Effects. Warnings and Precautions

For the Patient: Rituximab injection Other names: RITUXAN

Fifth Visit Posttest

All medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you.

Alcohol. Fits Hallucinations. Hallucinations Brain damage. Cirrhosis Gastritis. Diabetes Vomiting blood

For the Patient: Cyclosporine injection Other names: SANDIMMUNE I.V.

Tuberculosis (TB) how do we treat it?

GLEEVEC (imatinib mesylate) Capsules FACT SHEET

For the Patient: Fludarabine injection Other names: FLUDARA

For the Patient: Ponatinib Other names: ICLUSIG

ACUPUNCTURE SPECIFIC INTAKE FORM

Patient History Form

For the Patient: Trastuzumab emtansine Other names: KADCYLA

Athens Rheumatology Clinic, LLC Sana Makhdumi, MD

Docetaxel (Taxotere )

The Rehabilitation Institute Cancer Rehabilitation

New Patient Specialty Intake Form Department of Surgery

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

NORVASC 5 mg and 10 mg tablets

PULMONARY MEDICINE PATIENT QUESTIONNAIRE

Center for Advanced Wound Care New Patient Questionnaire Page 1 of 6

FMS Psychology, PLLC Adult Intake Form. Phone Number (Day): Phone Number (Evening):

Patient Information. Marital Status (Single, Married, Life Partner, Divorced, Widowed) CHIEF COMPLAINT

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

Capecitabine. Other Names: Xeloda. About This Drug. Possible Side Effects. Warnings and Precautions

Preparing for Your Immune Checkpoint Inhibitor (CPI) Treatment

New Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests:

Flecainide BNM. Please read this leaflet carefully before you start taking Flecainide BNM.

Welcome to the UCLA Center for East- West Medicine Primary Care

Where is your pain located? Please use the diagram below to indicate where most of your pain is located.

Nivolumab. Nivolumab

(sunitinib malate) for Kidney Cancer

PATIENT INFORMATION LEAFLET

Tuscarawas County Health Department. Vivitrol Treatment Consent

PATIENT INFORMATION LEAFLET CARZIN XL

Efavirenz, stavudine and lamivudine

Address Street Address City State Zip Code. Address Street Address City State Zip Code

TB CAN BE CURED IF YOU TAKE THE TB DRUGS CORRECTLY.

PRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic

The information you provide us will greatly help us provide the highest quality and most comprehensive care for you.

HAMILTON ANXIETY RATING SCALE (HAM-A)

PACKAGE LEAFLET: INFORMATION FOR THE USER Insomniger 10mg and 20mg Tablets (temazepam)

For the Patient: USMAVFIPI

Silver Child Development Center New Patient Questionnaire. Relation (circle) Biological Mother Stepmother Adoptive Mother

Jennifer Teitelbaum Palmer M.D Keswick Road Suite 100 Baltimore MD 21211

AMGEVITA (adalimumab)

Natalie Kilheeney L.Ac., Dipl. OM Licensed Acupuncturist & Herbalist

What You Need to Know About. TB Infection TUBERCULOSIS

It is very common to get symptoms like cough, sore throat, runny nose and watery eyes. Usually when you

City State Zip Code. Ethnic Background: Caucasian African-American Asian Hispanic Native American. Previous. Hobbies/Leisure activities:,,,

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

Capital Health Medical Center - Hopewell NEUROSURGICAL-ONCOLOGY Patient History

For the Patient: USMAVNIV

Managing the Patients Response to TB Treatment

Essential Wellness Of Illinois, LLC Health History Questionnaire Christine A. Renz L.Ac., Dipl OM, MSTOM

Please have your health insurance card(s), a valid picture ID, and any applicable copayment ready when you check-in.

Treatment and Monitoring

PHARMA DYNAMICS CLOPIDOGREL 75 mg PATIENT INFORMATION LEAFLET

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)

Frequently asked questions about Tuberculosis (TB) screening & prevention

Inner Balance Acupuncture

John Wayne Cancer Institute Dr. Foshag Dr. Faries Dr. Bilchik Dr. Leuchter

IMIPENEM+CILASTATIN RBX

MEDICATION GUIDE SUTENT

ALIGN ACUPUNCTURE AND HERBS LLC Rebekah V. Michaels MAOM, Diplomate OM, Lic Ac

[Agency Name & Agency Phone Number] Patient Name

Discussing TECENTRIQ (atezolizumab) with your healthcare team

It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

Sunitinib. Other Names: Sutent. About This Drug. Possible Side Effects. Warnings and Precautions

Patient Name: Date: Address: Primary Care Physician: Online Website On TV In print On the radio

Transcription:

Drug Resistant Tuberculosis Self-reporting of Drugrelated Adverse Events During Treatment Introduction This information has been prepared for people with tuberculosis (TB) that is resistant to the commonly used drugs (known as drug-resistant TB or DR-TB) to help them to understand any drug-related problems and actions that they should take. What is drug-resistant tuberculosis? Drug-resistant tuberculosis is caused by poor treatment - it can be that the wrong TB drugs were prescribed or that the person with TB didn t take all their TB drugs medicines as prescribed by the health care worker. It is also possible that a person who already has DR-TB, spreads the disease to others. What are the signs and symptoms of drug-resistant tuberculosis? The general symptoms are the same as TB which is sensitive to the commonly used TB drugs (known as drug-susceptible TB or DS-TB ): productive cough (brings up sputum) for 2 weeks or more, weight loss, fever, night sweats, chest pain, and a feeling of weakness. Why is important for a person suffering from drug-resisitant TB to avoid contact with others? It is important that someone suffering from drug-resistant TB stays separate from others (at hospital or at home) whilst they can spread the TB bacteria to others (are infectious to others). Once they stops being infectious (become non-infectious), separation is no longer needed. Why take your TB drugs for drug-resistant tuberculosis as directed? It is vital that you take your TB drugs each day and continue treatment until your assigned health care worker tells you to stop. You must continue your treatment even if you feel better. Your treatment can be set up at health facility, at home, or another location. The total treatment time for drug-resistant TB can take anywhere between 9 and 20 months and will be prescribed according to your test results and individual requirements. The health care worker will know and inform you when to stop taking your medicines.

What are adverse events? People can react differently to TB drugs, but all TB drugs can have harmful effects commonly known as adverse events. During your treatment, you may experience new physical or mental sensations. If you think that any of these reactions could be related to the TB drugs you are taking, you should call your health care worker immediately. Monitoring and management of adverse events Although not common with so-called first-line TB drugs used for treating DS-TB, serious adverse events of TB drugs, do happen with so-called second-line drugs used in the treatment of drug-resistant TB. When serious adverse events occur, they sometimes can be dangerous. Many TB drugs can be toxic to the liver, it is therefore important to immediately inform your health care worker or treatment supporter if you have nausea or vomiting, loss of appetite, your skin turns a yellow color ( jaundice ), you have dark urine, or a fever for more than three days without an obvious cause such a chest infection. Furthermore, health care workers need to be informed if you get a skin rash, an upset stomach, headaches, have trouble remembering things, feel anxious, depressed, irritable, or experience changes in your behavior. You also need to immediately inform the health care worker if you start to lose your balance, control of bodily movements, or hearing, experience numbness and/or and muscle cramping, or fast and/or irregular beating of your heart ( palpitations ). All adverse events will be monitored during your meetings with a health care worker or treatment supporter, as they will ask you about symptoms of common adverse events. For minor adverse events, you can continue your prescribed treatment. For adverse events that need additional investigation, tests will be done. If needed, you will be given other drugs to treat the adverse event. Once an adverse event is identified, and which happened after you started taking your TB drugs, it is important that you rate the degree of concern from the adverse event on a scale ranging from 1 (no concern) to 3 (a lot of concern) as a measure of how bad you think the adverse event is. What should you do? Each time you feel different than your normal self, it is necessary to: 1. Write down your observations on any possible drug-related adverse events and rate them from 1 to 3 as explained above (see Table 1 on the next page - Self-reporting form: Drug-related Adverse Events during DR-TB treatment). 2. Immediately report your observations to a health care worker by phone if the score is 2 or 3, or during the next appointment if the score is 1. 3. Carefully follow the health care worker s instructions to either continue, change, or stop your TB drugs.

Table 1: Self-reporting form: Drug-related Adverse Events during DR-TB treatment Rate how worried you are about the observed adverse event on a scale ranging from 1 (no concern) to 3 (a lot of concern) as a measure of how bad you think the adverse event is. Onset date End date Adverse events Description No 1 Moderate 2 A lot of 3 Anemia Anorexia Anxiety Arthralgia Depression Change in vision Confusion Diarrhea Dizziness Fatigue Gastritis Headache Hearing loss Insomnia Jaundice Myalgia Nausea or vomiting Pancreatitis Peripheral Neuropathy Rash Tinnitus Weakness or fatigue, looking pale Loss of appetite or change in the taste of the food Feeling nervous or anxious Joint pain Feeling sad, down, or depressed Change in vision Trouble remembering or confusion Diarrhoea or running stomach Feeling dizzy or light-headed Fatigue or loss of appetite Bloating, pain or gas in your stomach Headache Loss of hearing Difficulty falling or staying asleep Yellow color of the skin and whites of the eyes Muscle pain Nausea or vomiting Upper abdominal pain that goes through to your back, fever, nausea, and vomiting Pain, numbness, or tingling in the hands or feet Skin problems such as rash, dryness, or itching Ringing in the ears

Calendar for appointments and treatment monitoring During each visit/meeting with your health care worker or treatment supporter, ask them to note down the date and time of your next appointment on the calendar, as well what kind of test you will need to have to monitor the progress of your treatment (see Table 2: Treatment Calendar). This will help you to remember your next appointment and better prepare for the next visit. Table 2: Treatment Calendar Type of Activity Treatment Calendar: Months Type of Activity Treatment Calendar: Months Follow up visit with a health care worker Follow up sputum tests Other follow up monitoring tests Every time your treatment regimen changes, such as a change in the drugs, their dosages, or frequency, please ask your health care worker to write the changes down for you (see Figure 3: Administered Treatment Regimen). It will help the health care worker to tell whether any adverse event is due to one or other of the TB drugs that you are taking. Administered Treatment Regimen Date Regimen

Additional s The treatment for DR-TB can be difficult and long to complete, and you may require social support or support from your family members or other friends. It is important to discuss any concerns you may have with your health care worker(s), they can help organize any support that you need. Additional Information For any additional information, please contact your health care worker or the treatment supporter who is directly involved in your treatment and care, or any health staff at the facility, Address, Phone number Challenge TB 2019 www.challengetb.org The Global Health Bureau, Office of Infectious Disease, US Agency for International Development, financially supported this publication through Challenge TB under the terms of Agreement No. AID-OAA-A-14-00029. This publication is made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents are the responsibility of Challenge TB and do not necessarily reflect the views of USAID or the United States Government.